Effect of ex vivo treatment with rhTGFβ1 or a TGFβ1 inhibitor on monocyte responses to rgE stimulation. Monocytes and NK cells purified from PBMC collected from 10 RZV recipients (demographics in S4 Table) before vaccination (D0) and 90 days post-vaccination (D90) were combined ex vivo and stimulated with VZV-rgE. A subset of D0 monocyte & NK cocultures was also treated with the TGFβ1 inhibitor LY (D0 LY), and a subset of D90 cocultures were supplemented with rhTGFβ1. The graph shows individual data points, means and p values calculated by Friedman test for repeated measures with FDR correction. LY treatment of cells collected on D0 significantly increased their activation to levels similar to D90. Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0. by Michael J. Johnson (5818168)

“…Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0.…”

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. by Francesca Catto (21253435)

“…Each map represents a 3-dimensional view of statistically affected voxels (p < 0.05), where the red scale indicates a decrease in plaque count, and the cyan scale represents an increase. …”

Image 2_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

“…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”

Image 5_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

“…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”

Image 1_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

“…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”

Phase analysis data and within group correlations. by Aaron L. Sayler (19797446)

Subjects:

Effect of <i>slc43a3</i> deletion on resting blood pressure (systolic and diastolic) and heart rate of male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Summary of measured parameters. by Aaron L. Sayler (19797446)

Subjects:

Raw data. by Aaron L. Sayler (19797446)

Subjects:

ONSD modifications induced by arterial paCO₂ changes. by Marco Carbonara (11483575)

Subjects:

Table 1 - by Marco Carbonara (11483575)

Subjects:

Enrollment flow-chart. by Marco Carbonara (11483575)

Subjects:

ONSD at T14 and six months after ICU discharge. by Marco Carbonara (11483575)

Subjects:

Bland-Altman plot indicating the agreement between the optic nerve sheath diameter measured with CT scan and US. by Marco Carbonara (11483575)

Subjects:

Optic Nerve Sheath Diameter (ONSD) in mm, measured by ultrasound. by Marco Carbonara (11483575)

Subjects:

Sound stress exposure prolonged the period of decreased withdrawal threshold after complete Freund’s adjuvant (CFA) injection. by Satoka Kasai (3861115)

“…(B) 50% withdrawal threshold in CFA-treated mice exposed to sound stress. They showed a significant decrease in 50% withdrawal threshold on day 7 after CFA injection, and CFA-treated mice exposed to sound stress showed a significant decrease in 50% withdrawal threshold during days 7–21 after CFA injection (CFA, on day 7, ****<i>P</i> < 0.001 vs day 0, on day 10, ***<i>P</i> < 0.001 vs day0; CFA + stress, day 7, 10, 14, and 21, ****<i>P</i> < 0.0001 vs day 0, Dunnett’s test). …”

Differences in the effect of microcredit on the income increase of poverty-alleviated population under different production scales. by Yin Liu (50073)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects: